IDEXX Laboratories, Inc. [NASDAQ:IDXX]: Analyst Rating and Earnings
Pro stock traders frequently make sure to pay attention what expert market analysts are saying about a potential stock buy. Regarding IDEXX Laboratories, Inc. [IDXX] right now, the most recent ratings from Wall St. analysts that we can see right now is regarding the quarter that’s slated to end in December. On average, stock market experts give IDXX an Outperform rating. The average 12-month price forecast for this stock is $228.80, with the high estimate being $259.00, the low estimate being $150.00 and the median estimate amounting to $250.00. This is compared to its latest closing price of $192.22.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for IDEXX Laboratories, Inc. [IDXX] is sitting at 1.71. This is compared to 1 month ago, when its average rating was 1.89.
For the quarter ending in Sep-18 IDEXX Laboratories, Inc. [IDXX] generated $0.55 billion in sales. That’s 0.01% lower than the average estimate of $0.55 billion as provided by Wall Street analysts. The three indicators above suggest that on the whole, this stock is not presenting an attractive investment option, as there are too many red flags that don’t point to a high-value ROI.
Keep your eyes peeled for the next scheduled financial results to be made public for this company, which are scheduled to be released on Thu 7 Feb (In 27 Days).
Fundamental Analysis of IDEXX Laboratories, Inc. [IDXX]
Now let’s turn to look at profitability: with a current Operating Margin for IDEXX Laboratories, Inc. [IDXX] sitting at +20.97 and its Gross Margin at +55.73, this company’s Net Margin is now 15.20%. These measurements indicate that IDEXX Laboratories, Inc. [IDXX] is generating considerably more profit, after expenses are accounted for, compared to its market peers.
This company’s Return on Total Capital is 35.86, and its Return on Invested Capital has reached 29.60%. Its Return on Assets is 16.22.
Similarly, its Total Debt to Total Capital is 104.48, while its Total Debt to Total Assets stands at 73.60.
What about valuation? This company’s Enterprise Value to EBITDA is 34.17 and its Total Debt to EBITDA Value is 2.54. The Enterprise Value to Sales for this firm is now 7.81, and its Total Debt to Enterprise Value stands at 0.09.
Shifting the focus to workforce efficiency, IDEXX Laboratories, Inc. [IDXX] earns $259,087 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 7.84 and its Total Asset Turnover is 1.21. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 0.78 and its Current Ratio is 0.94. This company is not investing its short-term assets in an optimally efficient way, making it a riskier investment.
Let’s now turn our attention to trading performance: IDEXX Laboratories, Inc. [IDXX] has 86.76M shares outstanding, amounting to a total market cap of $16.72B. Its stock price has been found in the range of 163.46 to 256.22. At its current price, it has moved by -24.78% from its 52-week high, and it has moved 17.90% from its 52-week low.
This stock’s Beta value is currently 0.98, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 51.87. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is IDEXX Laboratories, Inc. [IDXX] a Reliable Buy?
Shares of IDEXX Laboratories, Inc. [IDXX], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.